January 12-15, 2026 | San Francisco Marriott Marquis, CA
ImmuneSensor Therapeutics (IMS) is a clinical-stage company advancing first and best-in-class small molecule inhibitors of cGAS to create novel treatments for diverse inflammatory and autoimmune diseases.